이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

전립선암 환자에서 과분극된 13C-피루베이트 +/- 13C,15N-요소를 이용한 자기공명(MR) 영상

2026년 11월 9일 업데이트: Robert Bok, MD, PhD

방사선 치료를 받고 있는 전립선암 환자에서 과분극된 13C-피루베이트 +/- 13C,15N-요소를 사용한 자기공명(MR) 영상화에 대한 2상 연구

This is a Phase 2 clinical study of hyperpolarized (HP) 13C-pyruvate (13C), 15N-urea (13C,15N) metabolic MR imaging in prostate cancer patients who are undergoing or have received radiation therapy for prostate cancer.

연구 개요

상세 설명

PRIMARY OBJECTIVES:

I. Part 1: To Optimize the imaging sequences that maximize signal-to-noise ratio (SNR) and intra-tumoral kPL and kPG in regions of tumor vs. adjacent benign tissue as assessed by mpMRI imaging characteristics.

II. Part 2A To perform HP 13C-MRI and measure the changes in tumoral kPL and kPG.

III. Part 2B: To perform HP 13C-MRI and study the metabolic effects (changes in tumor kPL and kPG).

IV. Part 3: To perform HP 13C-MRI at time of Biochemical Failure and measure tumoral kPL and kPG, in previously external beam radiation therapy (EBRT) treated patients.

SECONDARY OBJECTIVES:

I. To evaluate the intra-patient variability in intra-tumoral kPL and kPG with repeated dose studies (Part 1, 2 & 3).

II. To determine the association between peak intra-tumoral kPL observed on baseline imaging with serum PSA. (Part 2 & 3).

III. To determine the association between changes in intra-tumor kPL after 4-12 weeks of systemic hormone therapy and PSA response (Part 2B).

IV. To compare and contrast intra-tumoral kPL and kPG with Prostate Imaging Reporting and Data System (PI-RADS) version 2 and individual mpMRI parameters including apparent diffusion coefficient (ADC) on diffusion-weighted imaging (Part 1, 2 & 3).

V. To describe the frequency of up-grading of tumor with MR/US-guided fusion biopsy obtained following baseline HP-MRI exam. (Part 3).

VI. To further characterize the safety profile of HP C-13 pyruvate injections (Part 1, 2 & 3).

VII. For patients imaged with HP 13C-MRI at time of biochemical failure post-EBRT, correlate peak intra-tumoral kPL and kPG with radiotherapy dose distributions from EBRT course (Part 3).

VIII. For studies incorporating HP 13C-urea, the baseline and the on-treatment changes in urea AUC parameter will be measured and compared to kPL endpoints of the same lesions (Part 1, 2 & 3).

OUTLINE:

The study is divided into 3 parts. Part 1: Participants undergo imaging as part of a multi-parametric magnetic resonance imaging (mpMRI) exam to determine exact parameters for imaging.

Part 2A: Participants planned for external beam radiotherapy (EBRT) Part 2B: Participants with high-risk localized prostate cancer planned to receive primary radiation therapy with concurrent systemic hormone therapy Part 3: Evaluable EBRT participants scanned at time of biochemical failure and MR/US fusion-guided prostate biopsy within 12 weeks. Participants have the option of undergoing a follow up HP Pyruvate +/- Urea MR exam 6-15 months following the baseline scan.

All participants will receive a scan at baseline and other procedures may be performed as part of routine, non-interventional standard of care at the time of biochemical failure, including serial prostate-specific antigen (PSA) monitoring and gene expression profiling of tumor tissue. Participants will be followed for 24 months after last procedure or removal from study, or until death, whichever occurs first.

연구 유형

중재적

등록 (추정된)

161

단계

  • 2 단계

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 장소

    • California
      • San Francisco, California, 미국, 94143
        • University of California, San Francisco

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

18년 이상 (성인, 고령자)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

남성

설명

Inclusion Criteria:

  1. Participants must have biopsy-proven adenocarcinoma of the prostate, as determined by medical chart review.

  2. For:

    1. Part 1: Participants post-radiation therapy or currently considering EBRT.
    2. Part 2A: Participants currently scheduled for or considering EBRT (no neo-adjuvant therapy planned).
    3. Part 2B: Participants currently scheduled for or considering EBRT and neo-adjuvant therapy is planned. The participant has biopsy-proven adenocarcinoma of the prostate with high-risk disease, defined by the presence of at least two of following criteria: a tumor stage of T3 or T4, a Gleason score of 8 to 10, or a PSA level ≥40 ng/mL) and the participant must be planning to receive androgen deprivation therapy (ADT) with an Luteinizing hormone-releasing hormone (LHRH) agonist or antagonist. The addition of an androgen-receptor (AR) signaling inhibitor (e.g., abiraterone, bicalutamide,apalutamide, enzalutamide or darolutamide) will be allowed.
    4. Part 3: Participants who have previously received radiation treatment to the prostate and are exhibiting signs of biochemical failure, with planned fusion biopsy within 12 weeks following completion of baseline HP 13C pyruvate +/-urea mpMRI.
  3. Participant is able and willing to comply with study procedures and provide signed and dated informed consent.

  4. Eastern Cooperative Oncology Group (ECOG) performance status <= 1.

  5. Age >= 18 years old at time of study entry.

  6. Ability to understand and the willingness to sign a written informed consent document.

  7. Demonstrates adequate organ function as defined below:

    1. White Blood Cell count (WBC) >=4000 cells/μL.
    2. Hemoglobin ≥9.0 gm/dL.
    3. Platelets ≥75,000 cells/μL.
    4. Renal Function > 30 Epithelial Growth Factor Receptor (eGFR).

Exclusion Criteria:

  1. Evidence of pelvic regional or distant metastatic disease on conventional imaging (MRI, computed tomography or whole body bone scan) or prostate-specific membrane antigen (PSMA) Positron Emission Tomography (PET) imaging. PSMA-avid lymph nodes confined to the pelvis will be allowed if <1 centimeter (cm).
  2. Prostate biopsy performed within 14 days prior to baseline C-13 HP pyruvate MRI.
  3. Poorly controlled hypertension, with blood pressure at study entry > 160 mm Hg systolic or > 100 mm Hg diastolic. Treatment with anti-hypertensives and re-screening is permitted.
  4. Contraindication to or inability to tolerate MRI with endorectal coil (e.g. severe claustrophobia, presence of cardiac pacemaker, aneurysm clip, severe or painful hemorrhoids, rectal stricture).
  5. Congestive heart failure with New York Heart Association (NYHA) status >= 2.
  6. History of clinically significant ECG abnormality, including QT prolongation, a family history of prolonged QT interval syndrome or myocardial infarction within 6 months of study entry.

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 특수 증상
  • 할당: 무작위화되지 않음
  • 중재 모델: 병렬 할당
  • 마스킹: 없음(오픈 라벨)

무기와 개입

참가자 그룹 / 팔
개입 / 치료
실험적: Part 1: Image Optimization Group

Participants will undergo Hyperpolarized 13C-Pyruvate +/- 13C,15N-Urea imaging as part of a multi-parametric magnetic resonance imaging (mpMRI) exam, with the primary objective of optimizing imaging sequences and techniques to maximize signal-to-noise ratio of imaging modality.

Given IV

다른 이름들:
  • 13C-피루브산, 15N-우레아

Imaging scan

다른 이름들:
  • mpMRI
실험적: Part 2A: Prospective imaging (External beam radiotherapy (EBRT) Participants)

Participants with pre-planned, non-interventional stereotactic body radiotherapy (EBRT) will undergo an HP Pyruvate +/-Urea mpMRI exam at baseline, at 3 months post-EBRT treatment and at 1yr post-treatment.

Given IV

다른 이름들:
  • 13C-피루브산, 15N-우레아

Imaging scan

다른 이름들:
  • mpMRI

External beam radiotherapy given outside of this study

다른 이름들:
  • EBRT
실험적: Part 2B: Prospective imaging (High-risk localized prostate cancer)

Participants with with high-risk localized prostate cancer and have pre-planned, non-interventional primary radiation therapy (RT) with concurrent, systemic, non-interventional hormone therapy will undergo HP Pyruvate+/-Urea mpMRI at baseline prior to the start of systemic hormone therapy, 4-12 weeks after the initiation of systemic hormone therapy (prior to radiation therapy), at 3 months post-radiation therapy, and at +1yr post-radiation therapy.

Given IV

다른 이름들:
  • 13C-피루브산, 15N-우레아

Imaging scan

다른 이름들:
  • mpMRI

Radiation therapy given outside of this study

다른 이름들:
  • RT

Therapy given outside of this study as part of standard of care

다른 이름들:
  • 비개입적, 전신 호르몬 요법
실험적: Part 3: EBRT participants at time of biochemical recurrence (BCR)

Evaluable EBRT participants who undergo HP Pyruvate +/-Urea mpMRI at time of biochemical failure, followed by magnetic resonance (MR) / ultrasound (US) fusion-guided prostate biopsy within 12 weeks following baseline MR exam. Participants in this group have the option of undergoing a follow up HP Pyruvate +/-Urea MR exam 6-15 months following the baseline scan, to evaluate for any interval change.

Given IV

다른 이름들:
  • 13C-피루브산, 15N-우레아

Imaging scan

다른 이름들:
  • mpMRI

External beam radiotherapy given outside of this study

다른 이름들:
  • EBRT

Biopsies may be taken from Trans-rectal ultrasound (TRUS) -visible lesion at the urologist's discretion

다른 이름들:
  • 생검

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Signal-to-noise ratio (Part 1)
기간: Day of MR imaging (1 day)

A signal-to-noise ratio is defined as a MR/spectroscopy parameter, consisting of the HP C13-Pyruvate or Lactate signal (peak) relative to background noise level (baseline) in MRI spectra of the tissue.

Day of MR imaging (1 day)
Mean HP 13C-pyruvate to lactate metabolic rate of conversion (kPL) over time (Part 2A)
기간: Up to 24 months

The mean percent change in tumoral kPL between baseline and 1-year post-EBRT will be reported.

Up to 24 months
Mean HP 13C-pyruvate to glutamate metabolic rate of conversion (kPG) over time (Part 2A)
기간: Up to 24 months

The mean percent change in tumoral kPG between baseline and 1-year post-EBRT will be reported.

Up to 24 months
Mean change in on-treatment kPL over time (Part 2B)
기간: Up to 24 months

Mean percent change in tumoral kPL for participants receiving systemic hormone therapy between baseline and 1 -year post-EBRT will be reported.

Up to 24 months
Mean change in on-treatment kPG over time (Part 2B)
기간: Up to 24 months

Mean percent change in tumoral kPG for participants receiving systemic hormone therapy between baseline and 1 -year post-EBRT will be reported.

Up to 24 months
Mean kPL at time of biochemical failure (Part 3)
기간: Up to 24 months

The mean kPL for participants with biochemical failure will be reported.

Up to 24 months
Mean kPG at time of biochemical failure (Part 3)
기간: Up to 24 months

The mean kPG for participants with biochemical failure will be reported.

Up to 24 months

2차 결과 측정

결과 측정
측정값 설명
기간
Intra-patient variability of kPL
기간: Up to 12 months

Intra-patient variability in the kPL will be summarized by the intraclass correlation and presented with a 90% confidence interval when multiple HP-MRI scans are obtained for a participant.

Up to 12 months
Intra-patient variability of kPG
기간: Up to 12 months

Intra-patient variability in the kPG will be summarized by the intraclass correlation and presented with a 90% confidence interval when multiple HP-MRI scans are obtained for a participant.

Up to 12 months
Mean intra-tumoral kPL above and below the median PSA (Parts 2-3) and the mean serum PSA
기간: Up to 24 months

The study cohort will be dichotomized by mean intra-tumoral kPL obtained at baseline with median serum PSA and will be compared between the two dichotomized subgroups using Mann-Whitney test.

Up to 24 months
Correlation of kPL with Prostate Imaging Reporting and Data System (PI-RADS) version 2 classification score
기간: Up to 24 months

Spearman's rank order correlation coefficient will be used to determine the relationship between kPL with PI-RADS version 2 classification score (1 through 5; PI-RADS 1 - Very low (clinically significant cancer is highly unlikely to be present) PI-RADS 2 - Low (clinically significant cancer is unlikely to be present)). The Spearman's correlation coefficient (rs) measures the strength and direction of association between two variables. The Spearman correlation coefficient, rs, can take values from +1 to -1 where a value of +1 indicates a perfect association, an rs of 0 indicates no association and an rs of -1 indicates a perfect negative association. The closer rs is to 0, the weaker the association.

Up to 24 months
Correlation of kPG with PI-RADS version 2 classification score
기간: Up to 24 months

Spearman's rank order correlation coefficient will be used to determine the relationship between kPL with PI-RADS version 2 classification score (1 through 5; PI-RADS 1 - Very low (clinically significant cancer is highly unlikely to be present) PI-RADS 2 - Low (clinically significant cancer is unlikely to be present)). The Spearman's correlation coefficient (rs) measures the strength and direction of association between two variables. The Spearman correlation coefficient, rs, can take values from +1 to -1 where a value of +1 indicates a perfect association, an rs of 0 indicates no association and an rs of -1 indicates a perfect negative association. The closer rs is to 0, the weaker the association.

Up to 24 months
Proportion of participants with concordant mismatch of low HP 13C-urea perfusion (ureaAUC)
기간: Up to 24 months

A secondary endpoint will be to identify concordant mismatch of low HP 13C-urea perfusion (ureaAUC) in lesions assessed for kPL.

Up to 24 months
Mean percent change in kPL over time for participants with optional scan
기간: Up to 24 months

For the subset of participants who undergo optional follow up MR scan following baseline MRI, the mean percent change from baseline in kPL will be descriptively reported using summary statistics.

Up to 24 months
Number of participants with reported treatment-related adverse events
기간: From start of HP 13C-pyruvate MR imaging to 20 minutes after the procedure for all scans

The incidence of adverse events as graded by Common Toxicity Criteria version 5.0 will be determined

From start of HP 13C-pyruvate MR imaging to 20 minutes after the procedure for all scans

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

수사관

  • 수석 연구원: Robert Bok, MD, PhD, University of California, San Francisco

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2024년 9월 24일

기본 완료 (추정된)

2028년 12월 31일

연구 완료 (추정된)

2032년 10월 31일

연구 등록 날짜

최초 제출

2024년 4월 25일

QC 기준을 충족하는 최초 제출

2024년 4월 25일

처음 게시됨 (실제)

2024년 4월 30일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 11월 12일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 11월 9일

마지막으로 확인됨

2026년 10월 1일

추가 정보

이 연구와 관련된 용어

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

아니요

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

예

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

구독하다